The New Pharma Market Access Playbook: Rethinking Patient Access Strategy
- Tina Witte
- 7 days ago
- 2 min read
The old market access playbook is obsolete. High list prices offset by heavy PBM rebates no longer work. Between the Inflation Reduction Act (IRA), PBM reform, and direct-to-consumer pharmacy channels, the rules have changed — and so has the definition of a frictionless patient experience.
Here are the structural shifts redrawing the commercial landscape, and where biopharma commercial and strategy leaders should focus next.
How the IRA and PBM Reform Reshaped Market Access
Medicare price negotiation has compressed the window to recoup R&D costs. That's driving a shift away from traditional small molecules toward biologics and cell therapies with longer market exclusivity.
At the same time, PBM reform pushing toward 100% rebate pass-through is removing the incentive to favor high-priced drugs. The result is net-price competition: the lowest actual cost wins the formulary spot.
Price transparency is accelerating the same way. Government and benchmarking efforts are establishing a visible price floor, and manufacturers are responding with their own direct-to-consumer channels to protect margins and bypass the traditional supply chain.
But while regulation reshapes corporate finance, patients face the affordability hit immediately. Even modest price increases — kept small to avoid IRA inflation penalties — compound fast for patients on high-deductible plans. As payers push specialty drugs into coinsurance tiers, Patient Assistance Programs (PAPs) become a launch requirement, not an afterthought.
The Real Bottleneck: AI-Driven Prior Authorization
The biggest operational drag right now is utilization management — and it has become an automation arms race.
Insurers use payer AI engines to triage and deny prior authorizations at scale. Health systems fight back with provider AI that scans records to auto-draft appeals. This "AI vs. AI" loop sounds advanced, but it strands patients in the middle, delaying therapy for weeks and driving up prescription abandonment.
Winning here means moving from reacting to friction to predicting it.
Predicting Friction with Real-World Data
The advantage now belongs to teams that operationalize Real-World Data (RWD) and advanced analytics:
Outcome-based agreements. Tie payment to actual patient outcomes, aligning directly with payer demands.
Predictive prior authorization. Forecast denial risk before the script is written, and hand physicians pre-filled justification packets at the point of care.
Social Determinants of Health (SDoH) data. Flag patients likely to drop off therapy due to cost or transit barriers, and intervene proactively.
Three Patient Access Priorities for the Next 24 Months
Fund access early. Treat copay and PAP infrastructure as foundational launch pillars, not post-launch line items.
Integrate with providers. Deploy access tools that live inside provider workflows to clear automated payer hurdles.
Master value-based contracting. Build the data capabilities to compete on net price and risk-sharing frameworks.
Looking ahead, today's administrative friction will force a shift toward automated, pre-vetted prior authorization networks. And as manufacturer direct-to-consumer models mature, expect hybrid fulfillment that pairs direct shipping with local clinical hubs, stripping friction out of specialty distribution.
Patient access is now a dynamic, competitive advantage. Treating it as one is how innovations actually reach the people who need them.
Turn access strategy into competitive advantage. Fletcher CSI brings deep expertise across CI, MI, Strategic Decision Support, and Life Sciences, helping organizations anticipate change, sharpen decisions, and execute with confidence. To pinpoint where your access journey is stuck, contact Tina Witte, SVP of Life Sciences.
